Wird geladen...
Impact of obinutuzumab alone and in combination for follicular lymphoma
Although rituximab-based chemoimmunotherapy prolongs the survival of patients with follicular lymphoma (FL), this disease is considered incurable in most patients. Thus, new therapies are needed not only for those in the relapsed/refractory setting, but also for initial treatment. Obinutuzumab (G, G...
Gespeichert in:
| Veröffentlicht in: | Blood Lymphat Cancer |
|---|---|
| Hauptverfasser: | , |
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
Dove Medical Press
2017
|
| Schlagworte: | |
| Online Zugang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6467363/ https://ncbi.nlm.nih.gov/pubmed/31360086 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/BLCTT.S114173 |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|